Searched for
LYRICA
Russia fines WhatsApp for first time for not deleting banned contentAlthough WhatsApp's parent company Meta Platforms Inc was last year banned in Russia as an "extremist" organisation, the messenger app - wh...- Stocks in the news: ITC, Zomato, UPL, Adani Green, NMDC and TelcosAdani Green, Siemens, Indus Towers, Bosch, Godrej Properties, Voltas, Deepak Nitrite, Thermax, Bank of India, Brigade Enterprises, Saregama...
- Pfizer Q2 results: Net profit up 9% to Rs 143 croreRevenue from operations stood at Rs 636.26 crore for the quarter under consideration, as against Rs 595.41 crore a year ago, it added.
- Pfizer not yet ready to release COVID-19 vaccine data from late-stage trialPharma major Pfizer Inc said the company could release data on whether or not the vaccine works as early as this month.
- Add Pfizer, target price Rs 3,400: Centrum BrokingManagement is hopeful of achieving in-line or slightly better growth rate than the market.
- Pfizer plans to bring more global drugs to IndiaAlthough the company sells most of its top 20 global products in India, it is looking to bring in a couple of drugs, the patents of which h...
- Pfizer rallies over 6% on acquisition plans; scales above Rs 2000As per the report, Pfizer offered $90 per share in cash, a 39 percent premium to Hospira's closing stock price on Wednesday
- Pfizer posts Q3 profit fall, lowers outlookPfizer lowered its outlook for 2012 after a tough third quarter hit by the loss of exclusivity on its blockbuster Lipitor.
- Lupin to challenge Pregabalin ruling by US courtLupin Limited says it will challenge a US court order that prevents it from selling a low-cost generic version of Pfizer's nerve pain drug ...
- Unfair practices: Pharma cos GlaxoSmithkline, Pfizer, Johnson & Johnson and others fined $13 bn in 4 yearsGlaxoSmithkline, Pfizer, Johnson & Johnson, AstraZeneca, Merck, Abbot, Eli Lilly and Allergen have paid about $13 billion in fines to settl...
- Lupin gets USFDA approval for generic version of LyricaDrug firm Lupin today said it has received approval from the US health regulator to market generic version of Lyrica in the American market.
- Pfizer 4Q profit beats views as revenue up 6 pcPfizer Inc.'s new CEO on Tuesday outlined plans to reduce the company's spending and work force and focus more sharply on promising drugs a...
- Pfizer to snap up King Pharmaceuticals for $3.6 bnPfizer Inc on Tuesday said it will acquire King Pharmaceuticals in an all-cash deal worth $3.6 bn. The deal is expected to close in the Q4 ...
- Pfizer faces US probe, to pay $2.3 bnPfizer will pay $2.3 bn to settle a US investigation into illegal marketing of medicines, the largest agreement in such a case, and a subsi...
- Stocks to watch: Sun Pharma, Ess Dee, DLF, Neyveli Lignite, AGB Shipyard, Emami, RNRL, Kingfisher, Hotel LeelaOil prices slipped lower on Monday with benchmark crude for July down at $69.17 per barrel against previous close of $69.55.
- Pfizer charges Sun with another patent violationA legal battle between Pfizer and Sun Pharmaceutical has escalated.
- Pfizer profit dips 2 percent, sales fall much morePfizer Inc posted a 2 percent drop in first-quarter profit Tuesday, as cost-cutting by the world's largest drugmaker couldn't offset big dr...
- Pfizer’s Q3 profit up on downsizing, higher salesPfizer, the world’s biggest drugmaker, said profit tripled because of higher sales of the pain pill Lyrica and lower costs from the 11,000 ...
- Pfizer Q3 profit doubles to $3.4bnPfizer on Thursday said third-quarter earnings doubled from the year-ago quarter when it took a big merger-related charge, helped by strong...
- Pharma action hots up: UCB acquires Schwarz for $5.6bnUCB, the Belgian maker of the allergy drug Zyrtec, agreed to buy Schwarz Pharma for E4.4bn ($5.6bn) in cash and stock to gain new medicines...
Load More
